raav1-cb-haat
Gene therapyexperimental
Clinical trial activity
2 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2006 (NCT00430768)
Timeline
Indications
Studied for
Mechanism of action
- Alpha-1-antiproteinaseSupplementation
SERPINA1 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- raav1-cb-haat
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01054339 | Phase 2 | Mar 1, 2010 | Applied Genetic Technologies Corp, National Heart, Lung, and Blood Institute (NHLBI), Royal College of Surgeons, Ireland, University of Cincinnati, University of Colorado, Denver, University of Massachusetts |
| NCT00430768 | Phase 1 | Feb 1, 2006 | Alpha-1 Foundation, Applied Genetic Technologies Corp, National Center for Research Resources (NCRR), National Heart, Lung, and Blood Institute (NHLBI), University of Florida, University of Massachusetts |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Applied Genetic Technologies Corp | For profit | 2 | 1 | 2 | 2006 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 2 | 0 | 2 | 2006 |
| University of Massachusetts | Academic/Hospital | 2 | 1 | 2 | 2006 |
| Alpha-1 Foundation | Academic/Hospital | 1 | 0 | 1 | 2006 |
| National Center for Research Resources (NCRR) | Government | 1 | 0 | 1 | 2006 |
| Royal College of Surgeons, Ireland | Academic/Hospital | 1 | 0 | 1 | 2010 |
| University of Cincinnati | Academic/Hospital | 1 | 0 | 1 | 2010 |
| University of Colorado, Denver | Academic/Hospital | 1 | 0 | 1 | 2010 |
| University of Florida | Academic/Hospital | 1 | 0 | 1 | 2006 |
9 organizations
Page 1 / 1